隨著實(shí)驗(yàn)室關(guān)于轉(zhuǎn)化人類胚胎干細(xì)胞和誘導(dǎo)多能干細(xì)胞（iPS）成為可分泌多巴胺的神經(jīng)元研究進(jìn)展加速，越來越多的人開始懷疑,，比起現(xiàn)有的治療方法,，細(xì)胞移植是否在某種程度上對帕金森病有明顯益處。研究人員也日益認(rèn)識到,，帕金森癥患者不僅僅是多巴胺不足,。關(guān)于細(xì)胞治療帕金森病的討論可能很快變得更加激烈，歐洲科學(xué)家與北美的同事們一起協(xié)商取得歐洲委員會同意以進(jìn)行新終端細(xì)胞移植試驗(yàn),。主要研究者認(rèn)為,，該試驗(yàn)將改進(jìn)臨床方法，成為用多能干細(xì)胞或胚胎干細(xì)胞分化而來的細(xì)胞進(jìn)行治療的跳板,。然而,，一些人認(rèn)為這種試驗(yàn)方法是一種倒退,。（生物谷Bioon.com）
生物谷推薦原始出處：
Science 16 October 2009:DOI: 10.1126/science.326_358
Fetal Cells Again?
Constance Holden
As lab research on converting human embryonic stem (hES) cells and induced pluripotent stem (iPS) cells into dopamine-producing neurons proceeds apace, there's growing doubt in some quarters about whether cell transplants will ever show a clear benefit for Parkinson's disease beyond what can be achieved by existing therapies. And researchers are increasingly realizing that there's much more to Parkinson's than a dopamine shortage. The debate about cell therapy for Parkinson's may soon become more intense as scientists in Europe, in collaboration with colleagues in North America, are in final negotiations for a large European Commission grant to conduct a new fetal cell transplant trial. The trial will refine clinical methods and be a "steppingstone" to therapies with cells derived from iPS or hES cells, says the principal investigator. Yet news of the plans dismays some who think it's a step backward.
